Summary
Eli Lilly and Company (LLY) has announced the successful issuance and sale of $4.75 billion in aggregate principal amount of senior notes across multiple tranches, maturing between 2027 and 2064. This significant debt offering, which closed on August 14, 2024, generated net proceeds of approximately $4.96 billion after underwriting discounts. The company utilized this debt issuance to raise substantial capital, likely to support ongoing research and development, potential acquisitions, or general corporate purposes, aligning with its growth strategies in the pharmaceutical sector. Investors should note the diverse maturities and interest rates associated with these notes, ranging from 4.150% for the 2027 Notes to 5.200% for the 2064 Notes. The company has established terms for potential redemption and has outlined conditions under which the principal could become immediately due and payable in the event of a default. This financing action is a key event for the company, demonstrating its ability to access capital markets efficiently.
Key Highlights
- 1Eli Lilly & Co. issued and sold $4.75 billion in aggregate principal amount of senior notes.
- 2The notes have staggered maturity dates ranging from 2027 to 2064.
- 3Interest rates on the notes vary from 4.150% (2027 Notes) to 5.200% (2064 Notes).
- 4The offering closed on August 14, 2024.
- 5Net proceeds from the issuance were approximately $4.96 billion.
- 6The debt issuance was registered under a Form S-3 registration statement.
- 7The company has outlined provisions for note redemption and default.